<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-8VYWL4U8</identifier><date>2014</date><creator>Ilaš, Janez</creator><creator>Obreza, Aleš</creator><relation>documents/doc/8/URN_NBN_SI_doc-8VYWL4U8_001.pdf</relation><relation>documents/doc/8/URN_NBN_SI_doc-8VYWL4U8_001.txt</relation><format format_type="issue">5</format><format format_type="volume">65</format><format format_type="type">article</format><format format_type="extent">str. 337-343</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">3801201</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-8VYWL4U8</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="eng">alpha-adrenoreceptor antagonists</subject><subject language_type_id="slv">antagonisti adrenergičnih receptorjev alfa</subject><subject language_type_id="eng">benign hyperplasia of prostate</subject><subject language_type_id="slv">benigna hiperplazija prostate</subject><subject language_type_id="slv">lajšanje težav</subject><subject language_type_id="eng">testosterone 5-alpha reductase inhibitors</subject><subject language_type_id="slv">zaviralci testosteron-5-alfa reduktaze</subject><title>Drugs for treating benign hyperplasia of prostate</title><title>Zdravila za zdravljenje benigne hiperplazije prostate</title></Record>